Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
+$0.01 today
- Market cap
- $51.94M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
Volume 1.81M
Average 2.90M
HRTX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Heron Therapeutics, Inc.NASDAQ: HRTX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $5.89M rose 3964.8% year over year, ahead of the -63.0% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -13.5% a year.
Context
- Accounts receivables amounted to 6.9% of revenue in FY2025, down 6.1 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +3964.8% holds above the trailing-twelve-month pace of -63.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (10.71M) USD
- Year-over-year change
- +42.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.71M) | +42.9% |
| FY2024 | 2024-12-31 | (18.74M) | -131.8% |
| FY2023 | 2023-12-31 | (8.09M) | +51.1% |
| FY2022 | 2022-12-31 | (16.55M) | -360.6% |
| FY2021 | 2021-12-31 | 6.35M | — |
Accounts Receivables vs competitors
How HRTX compares with its peers on the latest reported figures
- HRTX's LTM Mar 2026 accounts receivables of $4.96M is the 2nd largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -63.0% is the lowest of 7, against a peer median of +214.5%.
- Accounts receivables amounts to 3.3% of revenue for HRTX, versus a peer median of 14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.88M | -20.2% | +92.8% | 326.1% | |
| LTM Mar 2026 | $4.96M | -63.0% | -13.5% | 3.3% | |
| LTM Mar 2026 | $4.26M | +247.4% | — | 14.7% | |
| LTM Mar 2026 | $3.64M | +1144.1% | — | 25.1% | |
| LTM Mar 2026 | $3.46M | -39.0% | — | 6.2% | |
| LTM Mar 2026 | $2.79M | +263.9% | +70.2% | 3.7% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $405.95K | +181.5% | — | — |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding HRTX) | $0 | +214.5% | +81.5% | 14.7% | |
Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (220.68M) | (182.02M) | (110.56M) | (13.58M) | (20.2M) |
| Depreciation & Amortization | 3.02M | 2.89M | 2.9M | 2.49M | 2.31M |
| Deferred Income Tax | 1.63M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46.85M | 42.98M | 32.85M | 12.96M | 10.34M |
| Change in Working Capital | (35.08M) | (10.51M) | 16.79M | (27.6M) | (31.88M) |
| Accounts Receivables | 6.35M | (16.55M) | (8.09M) | (18.74M) | (10.71M) |
| Inventory | (6.48M) | (6.19M) | 12.46M | (11.05M) | (31.05M) |
| Accounts Payables | 3.28M | (578K) | 15K | 8.47M | (2.72M) |
| Other Working Capital | (38.23M) | 12.81M | 12.4M | (6.28M) | 12.59M |
| Other Non-Cash Items | 904K | (251K) | (773K) | 3.2M | 11.83M |
| Operating Cash Flow | (203.35M) | (146.91M) | (58.79M) | (22.53M) | (27.59M) |
| Capital Expenditures | (3.02M) | (1.83M) | (1.55M) | (1.71M) | (317K) |
| Acquisitions (Net) | 32K | 227K | 13K | 27K | 0 |
| Purchases of Investments | (129.22M) | (145.68M) | (87.66M) | (103.09M) | (50.79M) |
| Sales of Investments | 164.94M | 143.96M | 107.19M | 123.48M | 67.01M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 98K |
| Investing Cash Flow | 32.73M | (3.32M) | 18M | 18.71M | 16.01M |
| Debt Repayment | 148.96M | 0 | 24.35M | 0 | 145.11M |
| Common Stock Issued | 7.07M | 75.06M | 29.76M | 940K | 19.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (150M) |
| Financing Cash Flow | 156.03M | 75.06M | 54.11M | 940K | 14.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (14.6M) | (75.18M) | 13.31M | (2.88M) | 2.85M |
| Free Cash Flow | (206.38M) | (148.74M) | (60.33M) | (24.24M) | (27.91M) |
Heron Therapeutics, Inc.
NASDAQ:HRTX
Intrinsic Alpha fair value
Locked
Current Price
$0.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.